The first-ever vaccine against the common winter bug Respiratory Syncytial Virus has been approved by the Food and Drug Administration.Arexvy was more than 84 percent effective at preventing lung infections in clinical trials and 94 percent effective against severe disease.It works by exposing the immune system to proteins from the surface of the virus, triggering the production of antibodies.
Load More
Load More